Reproductive Health Science Ltd

ASX:RHS ISIN:AU000000RHS4

Reproductive Health Science Ltd ASX:RHSReproductive Health Science (ASX:RHS) is an advanced biotech company that has successfully developed a test to assess embryos for chromosomal abnormalities prior to implantation as part of an of In-Vitro Fertilisation (IVF) cycle. The two component system has an immediate application to improve the success rate of IVF. The Company's lead product EmbryoCellect(TM) is aimed at improving health and research outcomes through the application of its frontier technologies with the initial primary focus of improving IVF success. Launched in 2014, EmbryoCellect(TM) contains reagents for 20 tests at a list price of AUD$3,600 per kit. RHS's assumption for business modelling purposes, based on IVF industry experience, is that there are 4 embryos per IVF cycle.

 

 
 
  

View in Other Languages

News

Asian Equities News 2015-07-15: EmbyroCellect Distribution Contract Signed For China and Hong Kong

🕔7/15/2015 11:45:25 AM 14132

Reproductive Health Science Ltd (ASX:RHS) said that it has signed an exclusive distribution agreement with Medicare International Trading Limited for the sale of EmbryoCellect(TM) in China, Hong Kong and Macau. Medicare is based in Hong Kong and distributes in mainland China through its Chinese company, Miaoquan Enterprise, which is based in Shenzhen.

Read Full Article

Reproductive Health Science Ltd (ASX:RHS) Appendix 4E Financial Report

🕔2/19/2015 9:21:39 AM 4632

On the 2 April 2014, Reproductive Health Science Ltd (ASX:RHS) successfully completed the acquisition of Reproductive Health Science Pty Ltd (now RHS Subsidiary Pty Ltd, 'RHS Subsidiary '), resulting in the issue of 19,120,704 fully paid shares in the Company.

Read Full Article

Reproductive Health Science Ltd (ASX:RHS) Signs Two New Distributor Agreements

🕔2/16/2015 9:21:01 AM 5277

Reproductive Health Science Limited (ASX:RHS) is pleased to advise it has signed 3-year exclusive distribution agreements with distributors based in Israel and South Africa, for the sale of its lead product EmbryoCellect(TM).

Read Full Article

Reproductive Health Science Ltd (ASX:RHS) Quarterly Report to December 2014

🕔1/30/2015 3:26:19 PM 4590

Reproductive Health Science Limited (ASX:RHS) ("RHS" or the "Company") announces its fourth quarter cash flow report for the year ending 31 December 2014.

Read Full Article

Reproductive Health Science Ltd (ASX:RHS) Enters Into Distributor Agreement for EmbryoCellect

🕔1/23/2015 10:25:42 AM 6786

Reproductive Health Science Limited (ASX:RHS) is pleased to advise it has signed a 3-year exclusive distribution agreement with SAR Healthline (P) Ltd for the sale of its lead product EmbryoCellectTM in India, Sri Lanka and Bangladesh.

Read Full Article

Reproductive Health Science Ltd (ASX:RHS) Launches Pre-Implantation IVF Screening Kit EmbryoCellect(TM)

🕔7/2/2014 12:44:37 PM 6808

Australian IVF-focussed company Reproductive Health Science Ltd (ASX:RHS) is pleased to advise Managing Director and CEO Dr Michelle Fraser has launched its lead product, EmbryoCellect(TM) at an international forum for reproductive medicine and embryology in Munich, Germany.

Read Full Article
###

15,099 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 13) (Last 30 Days: 59) (Since Published: 8869) 

Company Data

    Headquarters
  • BioSA Incubator
    40-46 West Thebarton Road
    Thebarton SA 5031
    Australia
  • Telephone
  • +61-8-8152-9383 
  • Fax
  • +61-8-8152-9474 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.rhsc.com.au
  • E:
  • michelle.fraser@rhsc.com.au